Scintigraphic detection of multidrug resistance in cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 4, 2000, Pages 327-337

  Del Vecchio, S ^a   Ciarmiello, A ^b   Salvatore, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

CANCER; DIAGNOSTIC IMAGING; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY;

EID: 0033779420     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.327     Document Type: Review

References (59)

1. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
2. Non-P-glycoprotein drug export mechanisms of multidrug resistance
3. Internal duplication and homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells
4. Function and regulation of the human multidrug resistance gene
5. MDR 1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine
6. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
7. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
8. Genetic dissection of the function of mammalian P-glycoproteins
9. Expression of a multidrug-resistance gene in human tumors and tissues
10. Multidrug resistance in breast cancer: A meta-analysis of MDR 1/gp 170 expression and its possible functional significance
11. Modulation of activity of the promoter of the human MDR1 gene by ras and p53
12. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter
13. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein
14. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution
15. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene
16. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome
17. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
18. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
19. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation
20. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein
21. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance
22. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET
23. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier
24. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant
25. The role of nuclear medicine imaging for the evaluation of patients with breast abnormalities
26. 99mTc-sestamibi in tumor imaging
27. Uptake and retention of hexakis (2methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells: Mithochondrial and plasma membrane potential dependence
28. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro
29. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat heart
30. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells
31. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors
32. Pharmacologic approaches to reversing multidrug resistance
33. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression
34. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors
35. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy
36. Different patterns of technetium-99m sestamibi uptake in multiple myeloma
37. Immunohistologic assessment of technetium-99-MIBI uptake in benign and malignant breast lesions
38. Technetium-99m-sestamibi: An indicator of breast cancer invasiveness
39. 99mTc-Sestamibi scan in untreated breast cancer patients
40. 99mTc-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients
41. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy
42. Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: Can we predict the response to chemotherapy in small cell lung cancer?
43. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas
44. Evaluation of therapy response in children with untrated malignant lymphomas using technetium-99m-Sestamibi
45. Tumor clearance of technetium 99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
46. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer
47. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer
48. The clinical role of MDR1 gene expression in human lung cancer
49. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer
50. Multidrug-resistant gene expression in small-cell lung cancer
51. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs
52. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP
53. Non-small-cell lung cancer functional imaging: Increased hexakis-2-methoxy-isobutyl-isonitrile minor clearance correlates with resistance to cytotoxic treatment
54. Technetium-99m-MIBI uptake in small cell lung cancer
55. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer
56. Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT
57. Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo
58. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-sestamibi
59. Cancer multidrug resistance